Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aurinia Pharmaceuticals ( (AUPH) ) just unveiled an update.
On March 30, 2026, Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences via a tender offer at $6.955 in cash per share plus a non‑transferable contingent value right. The CVR will entitle Kezar shareholders to potential additional cash tied to zetomipzomib’s development or disposition, proceeds from Kezar’s Everest and Enodia deals, and Kezar’s closing net cash above $50 million, net of certain post‑closing CVR costs.
Under the merger agreement, Aurinia must launch the tender offer by April 13, 2026, keep it open for 20 business days, and then complete a follow‑on merger that will make Kezar a wholly owned subsidiary if customary conditions are met. The deal, unanimously approved by Kezar’s board after a strategic review and backed by Tang Capital’s 9% tender commitment, is expected to close in the second quarter of 2026 and would expand Aurinia’s autoimmune pipeline with the first‑in‑class candidate zetomipzomib.
The most recent analyst rating on (AUPH) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
The score is driven primarily by the improved fundamentals (revenue scale-up, strong cash generation, and low leverage) and a generally positive earnings call with double-digit 2026 growth guidance. These strengths are tempered by weak technical signals and uncertainties around the sustainability of reported profitability given the material one-time tax benefits, alongside competitive and regulatory risks.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical needs. It markets LUPKYNIS, the first FDA‑approved oral therapy for adult patients with active lupus nephritis, and is developing aritinercept, a dual BAFF/APRIL inhibitor for potential use across autoimmune indications.
Kezar Life Sciences Inc. is a clinical-stage biopharmaceutical company developing novel small‑molecule therapeutics for immune‑mediated diseases and oncology. Its lead candidate, zetomipzomib, a selective immunoproteasome inhibitor, is being evaluated for autoimmune hepatitis and has potential applications in other chronic immune‑mediated disorders.
Average Trading Volume: 1,068,574
Technical Sentiment Signal: Buy
Current Market Cap: $2.08B
For an in-depth examination of AUPH stock, go to TipRanks’ Overview page.